Terms ending in 2035
Every in-force patent on Adimab, LLC's record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,390,964 | Polyclonal Mixtures of Antibodies, and Methods of Making and Using Them In force · High confidence | Adimab, LLC | In force | High confidence | |
| US 12,258,679 | Polyclonal Mixtures of Antibodies, and Methods of Making and Using Them In force · High confidence | Adimab, LLC | In force | High confidence | |
| US 12,733,934 | Adapter, Extension, and Connector Assemblies for Surgical Devices In force · High confidence | Adimab, LLC | In force | High confidence | |
| US 10,882,920 | Antibodies Against BACE1 and Use Thereof for Neural Disease Immunotherapy In force · High confidence | Adimab LLC | In force | High confidence | |
| US 11,008,403 | Anti-Transferrin Receptor / ANTI-BACE1 Multispecific Antibodies and Methods of Use In force · High confidence | Adimab LLC | In force | High confidence | |
| US 12,181,480 | Polyspecificity Reagents, Methods for Their Preparation and Use In force · Medium confidence | Adimab, LLC | In force | Medium confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.